Naveen Pemmaraju: Wonderful to attend the highly successful SOHO2024 meeting
Naveen Pemmaraju posted the following on LinkedIn:
“Wonderful to attend the highly successful SOHO2024 meeting held in Houston this week! Researchers and Healthcare Providers from around the world gathered to learn about the latest advances in malignant hematology (lymphoma, myeloma, acute and chronic leukemia, MDS, MPN, CAR-T/SCT/Immunotherapy) and to do some great networking with outstanding colleagues. A special shout-out to Janet Cesak and the entire SOHO2024 organizing team for such a well-done meeting!”
Source: Naveen Pemmaraju/LinkedIn
Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.
His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023